PL393578A1 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number
PL393578A1
PL393578A1 PL393578A PL39357811A PL393578A1 PL 393578 A1 PL393578 A1 PL 393578A1 PL 393578 A PL393578 A PL 393578A PL 39357811 A PL39357811 A PL 39357811A PL 393578 A1 PL393578 A1 PL 393578A1
Authority
PL
Poland
Prior art keywords
fusion protein
domain
sequence
terminus
anticancer fusion
Prior art date
Application number
PL393578A
Other languages
English (en)
Other versions
PL219845B1 (pl
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Piotr Kamil Rózga
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL393578A priority Critical patent/PL219845B1/pl
Priority to RS20170597A priority patent/RS56095B1/sr
Priority to CA2814597A priority patent/CA2814597C/en
Priority to PL12700215T priority patent/PL2661496T3/pl
Priority to US13/978,090 priority patent/US9175059B2/en
Priority to PT127002152T priority patent/PT2661496T/pt
Priority to JP2013547859A priority patent/JP5797773B2/ja
Priority to PCT/EP2012/050145 priority patent/WO2012093158A1/en
Priority to MEP-2017-131A priority patent/ME02756B/me
Priority to EA201391005A priority patent/EA025830B1/ru
Priority to CN201280003863.3A priority patent/CN103228788B/zh
Priority to SI201230978T priority patent/SI2661496T1/sl
Priority to HUE12700215A priority patent/HUE032576T2/en
Priority to EP12700215.2A priority patent/EP2661496B1/en
Priority to AU2012204900A priority patent/AU2012204900B2/en
Priority to BR112013016980-0A priority patent/BR112013016980B1/pt
Priority to SG2013032768A priority patent/SG190049A1/en
Priority to DK12700215.2T priority patent/DK2661496T3/en
Priority to MX2013007872A priority patent/MX339203B/es
Priority to KR1020137020558A priority patent/KR101950043B1/ko
Priority to ES12700215.2T priority patent/ES2628377T3/es
Priority to LTEP12700215.2T priority patent/LT2661496T/lt
Priority to NZ609219A priority patent/NZ609219B2/en
Priority to UAA201309548A priority patent/UA108778C2/ru
Publication of PL393578A1 publication Critical patent/PL393578A1/pl
Priority to IL226205A priority patent/IL226205B/en
Publication of PL219845B1 publication Critical patent/PL219845B1/pl
Priority to HRP20170905TT priority patent/HRP20170905T1/hr
Priority to CY20171100632T priority patent/CY1119149T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL393578A 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne PL219845B1 (pl)

Priority Applications (27)

Application Number Priority Date Filing Date Title
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne
EP12700215.2A EP2661496B1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
ES12700215.2T ES2628377T3 (es) 2011-01-05 2012-01-05 Proteína de fusión antineoplásica
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne
US13/978,090 US9175059B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
PT127002152T PT2661496T (pt) 2011-01-05 2012-01-05 Proteína de fusão anticancerígena
JP2013547859A JP5797773B2 (ja) 2011-01-05 2012-01-05 抗がん性融合タンパク質
PCT/EP2012/050145 WO2012093158A1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
MEP-2017-131A ME02756B (me) 2011-01-05 2012-01-05 Fuziona belančevina protiv raka
EA201391005A EA025830B1 (ru) 2011-01-05 2012-01-05 Слитый белок против злокачественной опухоли
CN201280003863.3A CN103228788B (zh) 2011-01-05 2012-01-05 抗癌融合蛋白
SI201230978T SI2661496T1 (sl) 2011-01-05 2012-01-05 Fuzijski protein proti raku
HUE12700215A HUE032576T2 (en) 2011-01-05 2012-01-05 Anti-cancer fusion protein
RS20170597A RS56095B1 (sr) 2011-01-05 2012-01-05 Fuziona belančevina protiv raka
AU2012204900A AU2012204900B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
KR1020137020558A KR101950043B1 (ko) 2011-01-05 2012-01-05 항암 융합 단백질
SG2013032768A SG190049A1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
DK12700215.2T DK2661496T3 (en) 2011-01-05 2012-01-05 FUSION PROTEIN AS ANTICANCING AGENT
MX2013007872A MX339203B (es) 2011-01-05 2012-01-05 Proteina de fusion anticancer.
BR112013016980-0A BR112013016980B1 (pt) 2011-01-05 2012-01-05 Proteína de fusão anticancerígena
CA2814597A CA2814597C (en) 2011-01-05 2012-01-05 Anticancer fusion protein
LTEP12700215.2T LT2661496T (lt) 2011-01-05 2012-01-05 Priešvėžinis sulietas baltymas
NZ609219A NZ609219B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
UAA201309548A UA108778C2 (xx) 2011-01-05 2012-05-01 Протираковий злитий протеїн
IL226205A IL226205B (en) 2011-01-05 2013-05-07 Fusion proteins, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of cancer
HRP20170905TT HRP20170905T1 (hr) 2011-01-05 2017-06-13 Antikancerogeni fuzijski protein
CY20171100632T CY1119149T1 (el) 2011-01-05 2017-06-15 Αντικαρκινικη πρωτεϊνη συντηξης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne

Publications (2)

Publication Number Publication Date
PL393578A1 true PL393578A1 (pl) 2012-07-16
PL219845B1 PL219845B1 (pl) 2015-07-31

Family

ID=45476512

Family Applications (2)

Application Number Title Priority Date Filing Date
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne

Country Status (25)

Country Link
US (1) US9175059B2 (pl)
EP (1) EP2661496B1 (pl)
JP (1) JP5797773B2 (pl)
KR (1) KR101950043B1 (pl)
CN (1) CN103228788B (pl)
AU (1) AU2012204900B2 (pl)
BR (1) BR112013016980B1 (pl)
CA (1) CA2814597C (pl)
CY (1) CY1119149T1 (pl)
DK (1) DK2661496T3 (pl)
EA (1) EA025830B1 (pl)
ES (1) ES2628377T3 (pl)
HR (1) HRP20170905T1 (pl)
HU (1) HUE032576T2 (pl)
IL (1) IL226205B (pl)
LT (1) LT2661496T (pl)
ME (1) ME02756B (pl)
MX (1) MX339203B (pl)
PL (2) PL219845B1 (pl)
PT (1) PT2661496T (pl)
RS (1) RS56095B1 (pl)
SG (1) SG190049A1 (pl)
SI (1) SI2661496T1 (pl)
UA (1) UA108778C2 (pl)
WO (1) WO2012093158A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012808A (es) 2013-03-12 2016-05-31 Molecular Templates Inc Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
JP2016520053A (ja) * 2013-05-06 2016-07-11 中国▲薬▼科大学Ｃｈｉｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用
CN106414483A (zh) 2014-01-27 2017-02-15 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
ES2971981T3 (es) 2017-01-25 2024-06-10 Molecular Templates Inc Moléculas de reconocimiento de células que comprenden efectores de la subunidad A de la toxina Shiga desinmunizados y epítopos de células T CD8+
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ252486A (en) 1992-04-29 1997-08-22 Univ Georgetown Blocking peptides capable of binding to ligands of the epidermal growth factor receptor (erbb-2) and their use in detecting such ligands
EP0835305B1 (en) 1995-06-29 2005-11-23 Immunex Corporation Cytokine that induces apoptosis
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7666989B2 (en) 2003-11-03 2010-02-23 Beijing Sunbio Biotech Co., Ltd. Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
EP1915626B1 (en) 2005-08-16 2011-11-09 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
SG191698A1 (en) 2008-06-30 2013-07-31 Univ Pennsylvania Fn14/trail fusion proteins
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
JP5759557B2 (ja) * 2010-12-03 2015-08-05 アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． 抗がん融合タンパク質

Also Published As

Publication number Publication date
HRP20170905T1 (hr) 2017-09-08
IL226205A0 (en) 2013-07-31
EA201391005A1 (ru) 2013-11-29
BR112013016980A2 (pt) 2020-08-04
AU2012204900B2 (en) 2014-12-18
IL226205B (en) 2018-10-31
SG190049A1 (en) 2013-06-28
EP2661496A1 (en) 2013-11-13
CN103228788B (zh) 2016-09-07
RS56095B1 (sr) 2017-10-31
ME02756B (me) 2018-01-20
LT2661496T (lt) 2017-07-10
BR112013016980B1 (pt) 2022-10-11
DK2661496T3 (en) 2017-07-03
AU2012204900A1 (en) 2013-05-02
EA025830B1 (ru) 2017-02-28
US9175059B2 (en) 2015-11-03
NZ609219A (en) 2014-06-27
JP2014504868A (ja) 2014-02-27
WO2012093158A1 (en) 2012-07-12
HUE032576T2 (en) 2017-09-28
PL219845B1 (pl) 2015-07-31
CN103228788A (zh) 2013-07-31
ES2628377T3 (es) 2017-08-02
MX339203B (es) 2016-05-13
CA2814597C (en) 2019-01-08
UA108778C2 (xx) 2015-06-10
SI2661496T1 (sl) 2017-09-29
PL2661496T3 (pl) 2017-08-31
KR101950043B1 (ko) 2019-02-19
US20130288963A1 (en) 2013-10-31
CA2814597A1 (en) 2012-07-12
PT2661496T (pt) 2017-06-26
KR20140036143A (ko) 2014-03-25
EP2661496B1 (en) 2017-03-15
CY1119149T1 (el) 2018-02-14
MX2013007872A (es) 2013-07-30
JP5797773B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
PH12014501083A1 (en) Anticancer fusion protein
MX339203B (es) Proteina de fusion anticancer.
MX337436B (es) Proteina de funsion anticancer.
MX2014008028A (es) Proteina de fusion anticancerigena.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
RU2021134101A (ru) Модифицированная j-цепь
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2012143477A3 (en) Anticancer fusion protein
EP3363458A3 (en) A peptide
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PH12017500742A1 (en) Statherin peptides
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
TH159052A (th) ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein)